REFERENCES
1. Low YH, Ang ES, Goh AS, Sundram FX, Sin FL. Technetium-99m (Tc-99m) diphosphono-propanedicarboxylic acid bone tracer uptake and Tc99m sestamibi distribution in cardiac amyloidosis - a case report. Ann Acad Med Singapore 1995;24:898-901.
2. Yen TC, Tzen KY, Chen KS, Tsai CJ. The value of gallium-67 and thallium-201 whole-body and single-photon emission tomography images in dialysis-related beta 2-microglobulin amyloid. Eur J Nucl Med 2000;27:56-61.
3. Wechalekar K, Ng FS, Poole-Wilson PA, et al. Cardiac amyloidosis diagnosed incidentally by bone scintigraphy. J Nucl Cardiol 2007;14:750-3.
4. Kodama K, Hamada M, Kuwahara T, et al. Rest-redistribution thallium-201 myocardial scintigraphic study in cardiac amyloidosis. Int J Card Imaging 1999;15:371-8.
5. Hauser W, Atkins HL, Richards P. Amyloidosis of the heart. Possible pitfall in the diagnosis of pericardial effusion by scintillation scanning. JAMA 1968;204:628-30.
6. Gerson MC, Colthar MS, Fowler NO. Differentiation of constrictive percarditis and restrictive cardiomyopathy by radionuclide ventriculography. Am Heart J 1989;118:114-20.
7. Hongo M, Fujii T, Hirayama J, Kinoshita O, Tanaka M, Okubo S. Radionuclide angiographic assessment of left ventricular diastolic filling in amyloid heart disease: a study of patients with familial amyloid polyneuropathy. J Am Coll Cardiol 1989;13:48-53.
8. Clements IP, Olson LJ, Scanlon PD, Gertz MA, Mullany CJ. The effect of respiration on left ventricular diastolic filling as assessed by radionuclide ventriculography. Nucl Med Commun 2000;21:55-63.
9. Arbab AS, Koizumi K, Toyama K, Arai T, Yoshitomi T, Araki T. Scan findings of various myocardial SPECT agents in a case of amyloid polyneuropathy with suspected myocardial involvement. Ann Nucl Med 1997;11:139-41.
10. Ohta H, Endo K, Kanoh T, Konishi J, Kotoura H. Technetium-99m (V) DMSA uptake in amyloidosis. J Nucl Med 1989;30:2049-52.
11. Gazzilli M, Bertoli M, Albano D, et al. Cardiac amyloidosis incidentally detected by 18F-FDG PET/CT. J Nucl Cardiol 2020;27:2429-31.
12. Tanaka H, Hosono M, Kanagaki M, et al. A case of cardiac amyloidosis incidentally detected by bone scintigraphy. Asia Ocean J Nucl Med Biol 2021;9:71-5.
13. Tuominen H, Haarala A, Tikkakoski A, Kähönen M, Nikus K, Sipilä K. 18-FDG-PET in a patient cohort suspected for cardiac sarcoidosis: Right ventricular uptake is associated with pathological uptake in mediastinal lymph nodes. J Nucl Cardiol 2020;27:109-17.
14. Tanaka M, Hongo M, Kinoshita O, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol 1997;29:168-74.
15. Hongo M, Urushibata K, Kai R, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am Heart J 2002;144:122-9.
16. Lekakis J, Dimopoulos MA, Prassopoulos V, et al. Myocardial adrenergic denervation in patients with primary (AL) amyloidosis. Amyloid 2003;10:117-20.
17. Noordzij W, Glaudemans AW, van Rheenen RW, et al. (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging 2012;39:1609-17.
18. Coutinho MC, Cortez-Dias N, Cantinho G, et al. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy. Circ Cardiovasc Imaging 2013;6:627-36.
19. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990;323:508-13.
20. Hazenberg BP, van Rijswijk MH, Piers DA, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 2006;119:355.e15-24.
21. Aprile C, Marinone G, Saponaro R, Bonino C, Merlini G. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med 1995;22:1393-401.
22. Schaadt BK, Hendel HW, Gimsing P, Jønsson V, Pedersen H, et al. 99mTc-aprotinin scintigraphy in amyloidosis. J Nucl Med 2003;44:177-83.
23. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19.
24. Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 2013;54:213-20.
25. Choi SR, Golding G, Zhuang Z, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 2009;50:1887-94.
26. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010;51:913-20.
27. Yang L, Rieves D, Ganley C. Brain amyloid imaging--FDA approval of florbetapir F18 injection. N Engl J Med 2012;367:885-7.
28. Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 2014;41:1652-62.
29. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68:319-29.
30. Lhommel R, Sempoux C, Ivanoiu A, Michaux L, Gerber B. Is 18F-flutemetamol PET/CT able to reveal cardiac amyloidosis? Clin Nucl Med 2014;39:747-9.
31. Dietemann S, Nkoulou R. Amyloid PET imaging in cardiac amyloidosis: a pilot study using 18F-flutemetamol positron emission tomography. Ann Nucl Med 2019;33:624-8.
32. Möckelind S, Axelsson J, Pilebro B, Lindqvist P, Suhr OB, Sundström T. Quantification of cardiac amyloid with [18F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis. Amyloid 2020;27:191-9.
33. Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-35.
34. Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. Cardiac amyloid imaging with 18F-Florbetaben PET: a pilot study. J Nucl Med 2016;57:1733-9.
35. Kircher M, Ihne S, Brumberg J, et al. Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imaging 2019;46:1407-16.
36. Genovesi D, Vergaro G, Giorgetti A, et al. [18F]-Florbetaben PET/CT for Differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions. JACC Cardiovasc Imaging 2021;14:246-55.
38. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84.
39. Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:470-8.
40. Kristen AV, Haufe S, Schonland SO, et al. Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol 2013;164:179-84.
41. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659-70.
42. Falk RH, Lee VW, Rubinow A, Hood WB, Cohen AS. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol 1983;51:826-30.
43. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195-201.
44. Cappelli F, Gallini C, Di Mario C, et al. Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. J Nucl Cardiol 2019;26:497-504.
45. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.
46. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol 2019;26:2065-123.
47. Musumeci MB, Cappelli F, Russo D, et al. Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis. JACC Cardiovasc Imaging 2020;13:1314-21.
48. Pilebro B, Suhr OB, Näslund U, Westermark P, Lindqvist P, Sundström T. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci 2016;121:17-24.
49. Wakfie-Corieh CG, Ramos López N, Saiz-Pardo Sanz M, Pérez Castejón MJ, Vilacosta I. Not all heart uptakes on 99mTc-DPD scintigraphy are amyloidosis: chloroquine-induced cardiomyopathy. Clin Nucl Med 2021;46:e188-9.
50. Chimenti C, Alfarano M, Maestrini V, et al. False-positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic cardiomyopathy. ESC Heart Fail 2021; doi: 10.1002/ehf2.13339.
51. Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol 2016;25:413-7.
52. Segall G, Delbeke D, Stabin MG, et al. SNM. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med 2010;51:1813-20.
53. Trivieri MG, Dweck MR, Abgral R, et al. 18F-Sodium fluoride PET/MR for the assessment of cardiac amyloidosis. J Am Coll Cardiol 2016;68:2712-4.
54. Morgenstern R, Yeh R, Castano A, Maurer MS, Bokhari S. 18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. J Nucl Cardiol 2018;25:1559-67.
55. Ng QKT, Sethi P, Saunders TA, Pampaloni MH, Flavell RR. Discordant findings on 18F-NaF and 99mTc-HDP bone scans in a patient with ATTR cardiac amyloidosis. Clin Nucl Med 2018;43:e89-92.
